Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Take a walk, beat chemo side effects: new study tests simple exercise breaks

NCT ID NCT06923397

Symptom relief Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a 12-week program of short exercise breaks (walking, cycling, resistance bands) can improve heart health and reduce chemotherapy side effects in 24 newly diagnosed lymphoma patients. Participants will use activity trackers and get coaching to interrupt long periods of sitting. The main goal is to see if the program is feasible and acceptable, with secondary measures of blood sugar and insulin resistance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
exercise program (walking, cycling, resistance band exercises)
What this could lead to
If it works, this could show that simple exercise breaks during chemo improve heart health and reduce treatment side effects for lymphoma patients.
What could go wrong
This is a small, early feasibility study with only 24 participants, so results may not apply to everyone. The program requires commitment and may be hard for some patients to complete.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ability to understand and the willingness to sign informed consent prior to any study- related procedures. * Patients diagnosed with lymphoma. * Will receive first line R-CHOP or POLA-R-CHP chemotherapy regimens, patients do not need to be within a certain timeframe from diagnosis. * Aged ≥18 years; due to the rarity of the disease in those \<18 years, this age bracket will not be included. * Engaging in ≤60-minutes of structured moderate or vigorous intensity exercise. * Have physician clearance to participate in exercise. * Speak English. * Willing to travel to Dana-Farber Cancer Institute for necessary data collection and exercise sessions. * Access to a phone that can receive text messages. Exclusion Criteria: * Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities likely require supervised exercise for safety, and part of this study involves unsupervised exercise; therefore, for safety reasons, these persons are excluded. * Participate in more than 60 minutes of structured moderate-to-vigorous exercise per week over the last month. Excess additional exercise is a confounding factor in assessing the effect of the current interrupted sedentary time intervention. * Patients receiving treatment for other active malignancies (except basal cell carcinoma). This study is exclusively targeting lymphoma chemotherapy-related effects. * Patients currently taking weight loss drugs. * Subjects who in the opinion of the investigators may not be able to comply with the safety monitoring requirements of the study. * Unable to travel to DFCI Longwood campus for necessary data collection and chemotherapy infusions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma lymphoma lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma Sedentary Behavior

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphoma Lymphoma, Hodgkin Lymphoma, non-Hodgkin Sedentary behavior

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.